Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Mastectomie bij borstkanker vereist teamwerk van chirurg, patholoog en borstradioloog
jun 2025 | Borstkanker